Australia's most trusted
source of pharma news
Wednesday, 27 August 2025
Posted 25 August 2025 AM
The PBAC has knocked back MSD's bid for Keytruda to have a broad listing for all TGA-registered indications, with MSD challenging the "bewildering" reason given.
At its July meeting, the PBAC rejected MSD's proposal for a multi-indication listing for Keytruda in a range of advanced or metastatic cancers, for which the pharma has been pushing for a number of years alongside a similar proposal from BMS for its Opdivo and Yervoy combination.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.